A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

March 31, 2003

Study Completion Date

March 31, 2003

Conditions

Secondary HyperparathyroidismEnd Stage Renal Disease

Interventions

DRUG

AMG 073

30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally

DRUG

Placebo

30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally